Five years after raising €30 million in a Series A financing round, Confo Therapeutics NV has completed another fundraising – this time for €60 million to advance a pipeline of therapies that modulate G-protein coupled receptors, one of the most difficult set of targets for drug development. The new round was led by Ackermans & van Haaren and included participation from the new investors Driehaus Capital Management and Quest for Growth.
Mission Therapeutics Ltd of the UK, which is developing therapies targeting mitochondrial dysfunction, has received $5.2 million in grant funding to progress its lead small molecule drug for Parkinson’s disease into early clinical development. The award comes from the Michael J Fox Foundation and Parkinson’s UK and follows the disclosure of promising data from healthy volunteers that the drug, MTX325, has a good safety profile and can penetrate the blood-brain barrier.
A venture syndicate led by Novo Holdings A/S, with participation from EQT Life Sciences, has raised $100 million for Asceneuron SA enabling it to advance a new product for Alzheimer’s disease. Based in Lausanne, Switzerland, Asceneuron is developing a small molecule drug, ASN51, that inhibits an enzyme implicated in the aggregation of proteins in the brain. This is thought to have application for both Alzheimer’s and Parkinson’s diseases, as well as amyotrophic lateral sclerosis.
Destiny Pharma Plc has decided to exit the AIM market of the London Stock Exchange and go private in order to raise money for the Phase 3 development of its lead antibiotic product XF-73 Nasal. The wholly-owned product delivered promising data in a Phase 2 study and has been poised for the next stage pending a licensing partner.
A syndicate of leading European and US investors has raised €63 million for SciRhom GmbH of Germany which is developing a treatment for autoimmune diseases by modulating an enzyme controlling several major signalling pathways. The Series A financing will enable SciRhom to bring its lead product candidate – a monoclonal antibody – into clinical development before the end of the year. The investment round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital and Wellington Partners. PhiFund Ventures of the US also participated.
Eli Lilly and Co is to pay $3.2 billion to acquire a US company with a pipeline of preclinical and clinical assets targeting integrin molecules for the treatment of gastrointestinal and other chronic diseases. The company, Morphic Holding Inc, is located near Boston and has a lead product, MORF-057, in Phase 2 for the potential treatment of ulcerative colitis and Crohn’s disease. Lilly is to pay $57 per share in cash for the company, which represents a premium of about 79% over the company’s closing share price on 5 July.
Zealand Pharma A/S completed an upsized equity offering on 26 June with the placement of 8.35 million shares with investors raising gross proceeds of DKK 7 billion ($1 billion). This will enable it to finance its prospective peptide-based medicines for obesity and metabolic and rare diseases well into the future. The directed share issue and private placement exceeded the initial targeted amount by $100 million.
Denmark-based Zealand Pharma A/S has announced an offering of new shares which is expected to raise DKK 6.3 billion ($900 million). This will be done by way of a private placement directed at institutional and professional investors in Denmark and elsewhere. Zealand Pharma is one of a growing number of companies developing new drugs for obesity and fibrosis. Its peptide-based medicines, also intended to treat rare diseases, include two marketed products and three in late-stage development.
Pfizer Inc has entered into a partnership with a Cambridge, US, based venture capital group and its network of drug discovery and development companies, to identify proteins that might become the basis of new drugs for obesity. The venture capital group is Flagship Pioneering and the drug discovery activities are located at Pioneering Medicines, an in-house unit of Flagship, and Profound Therapeutics, a Flagship spin-off company. Pfizer has been collaborating with Pioneering Medicines since 2023.
A new research project based in Denmark is to examine whether changes in the human microbiome can potentially cause cardiometabolic diseases such as obesity, type 2 diabetes and cardiovascular disease. Announced on 22 May, the project will be initially financed by the Novo Nordisk Foundation, a philanthropic organisation whose assets are managed by Novo Holdings. Novo Holdings is the controlling shareholder of Novo Nordisk A/S, developer of the obesity drugs liraglutide and semaglutide.